← Back to Reports

BillionToOne (BLLN): Unsupported Billing Claims – Fuzzy Panda Research

Fuzzy Panda Research says Tennessee Medicaid found 53 of 53 BillionToOne claims unsupported and refers the company for suspected fraud. Our take inside.

Medicaid investigators referred the company for suspected fraud after finding every reviewed claim unsupported.

Every one of the 53 billing claims that Tennessee Medicaid investigators reviewed from BillionToOne came back unsupported, a 100% error rate that preceded a formal referral to the state's Medicaid Fraud Division. The finding sits alongside allegations that BillionToOne's carrier-screening attachment rate, cited at 88% of NIPT tests in Michigan Medicaid data, runs nearly three times competitors' rates and may reflect billing for medically unnecessary retesting. Fuzzy Panda Research, which holds a short position in BillionToOne, argues these practices, together with allegedly undisclosed regulatory scrutiny and misleading product marketing, could erase a majority of the company's EBITDA.

Ticker: BLLN (BillionToOne, Inc.)
Research Firm: Fuzzy Panda Research
Report URL: https://fuzzypandaresearch.com/billiontoone-undisclosed-fraudulent-deductible-capping-medicaid-inappropriate-billing/?utm_source=rss&utm_medium=rss&utm_campaign=billiontoone-undisclosed-fraudulent-deductible-capping-medicaid-inappropriate-billing&ref=shortreport.fyi
Report date: 2026-11-18
Position Disclosure: Fuzzy Panda Research states it holds a short position in BillionToOne, Inc. and stands to profit if the stock price declines.

Published by Fuzzy Panda Research on 2026-11-18.


The Short Report's Take

The strongest material in this report is the Tennessee record. According to Fuzzy Panda Research, FOIA documents show TennCare's Office of Program Integrity concluded "a credible allegation of fraud has been established," identified a "Pattern of Inappropriate Billing," and referred BillionToOne to the Tennessee Bureau of Investigation's Medicaid Fraud Division, with a review finding all 53 sampled claims unsupported. That is a government record, not an inference, and it is the piece a holder should weigh most heavily, since it points to a pre-IPO issue the report says was never disclosed to investors.

Much of the rest rests on extrapolation and anonymous sourcing. The estimated $45 million to $130 million EBITDA hit from alleged excess carrier testing, and the $1.2 billion potential False Claims Act exposure, are built by projecting Michigan Medicaid data nationwide, which Fuzzy Panda Research itself frames as a modeled scenario rather than a confirmed figure. Claims about sales pressure, co-pay waivers as inducements, and oncology test reliability come largely from former employees, physicians, and a single secret recording, none independently corroborated in the inputs. The report cites no regulator or auditor action beyond the Tennessee referral's "MFCD Review" status, and states that BillionToOne had not responded to its allegations; a call to one physician's office manager about alleged phlebotomy overpayments went unreturned.

The source report does not state the stock's price reaction to publication or disclose short interest figures beyond Fuzzy Panda Research's own position.

Related coverage on The Short Report:


Thesis

Fuzzy Panda Research, in a short report on BillionToOne (BLLN), argues the company's growth and valuation depend on allegedly improper carrier-testing billing, undisclosed Medicaid scrutiny, and overstated product performance.

  • CPT Code Switching: Tennessee investigators allege BillionToOne billed "unlisted" CPT codes averaging $2,380 per claim, versus $62 to $343 for more appropriate codes, after regulators flagged unlisted codes as "often an area of abuse."
  • Unsupported Billing Pattern: A Tennessee claims review found a 100% error rate across all 53 claims examined, with one referring provider accounting for 27% of total paid claims.
  • Carrier-Testing Overbilling: Michigan Medicaid data show BillionToOne attached carrier screening to 88% of NIPT tests, versus 32% for Natera and 31% for Myriad, a rate the report calls roughly 120% above its estimated theoretical maximum given that only 39% to 40% of pregnancies are first pregnancies.
  • Sales Pressure to Inflate Attachment: Former sales representatives say the company monitored carrier-attachment rates and treated carrier screening as a "good money driver," with one rep stating an 88% to 90% rate would raise "red flags."
  • No-Verification Co-Pay Waivers: A sales document reportedly states "no W2 or additional paperwork is required to qualify" for financial assistance, and a recorded 2026 sales pitch has a representative saying the company does not verify income "with W2s or anything like that," even for six-figure households.
  • Oncology Reliability Gaps: Physicians describe Northstar Response results that diverged from clinical scans, with one oncologist saying reliance on the test over imaging "would have done the patient a significant harm."
  • NIPT False Negatives: A Journal of Cystic Fibrosis letter signed by five doctors, including a paid BillionToOne medical adviser, describes three infants classified low risk by Unity who were later diagnosed with cystic fibrosis, odds the physicians put at "8 in 1 million."
  • Insider Selling Amid Rising Receivables: Six top insiders sold an estimated $58.5 million of stock since the May 2026 lockup expiration and registered plans for roughly $24.5 million more, as accounts receivable grew 155% year over year against 47% revenue growth.

Catalysts

  • Tennessee Medicaid Fraud Division outcome: Resolution, expansion, or enforcement action in the TBI Medicaid Fraud Division review, timing not specified, would confirm or dispel the fraud referral at the center of the thesis.
  • Additional state Medicaid FOIA results: Pending requests from Alabama and follow-up Texas data on carrier testing, no date given, could corroborate or undercut the overbilling pattern alleged in Tennessee and Michigan.
  • Insurer reimbursement moves: Further payer action following Ambetter's early-2026 rejection of code 0499U, or the practical terms of BillionToOne's Elevance resolution, would signal whether reimbursement pressure is spreading.
  • Illumina patent litigation: A ruling or royalty outcome in Illumina's pending suit, which a former executive called the "single largest risk" to Unity revenue, could directly cut into test economics.
  • Complete Genomics/CFIUS review: The sale of supplier Complete Genomics to Swiss Rockets remained pending CFIUS review more than 260 days after its February 2026 announcement; completion, failure, or a supply disruption would affect Unity's manufacturing base.
  • New insider sales window: The additional $24.5 million in planned 10b5-1 sales was expected to open roughly one month after the report, adding to supply pressure on shares.

Company Response

The report does not describe a direct company response to its core allegations. It states that its authors placed multiple calls to a physician's office manager to ask about alleged above-market blood-draw payments, and that the calls were not returned. Beyond that, the report says BillionToOne could clarify matters through disclosure of any state or federal Medicaid investigations, but it does not indicate BillionToOne provided a response to the specific findings in the report. Separately, CFO Ross Taylor addressed rising accounts receivable on the company's Q1 2026 earnings call, attributing about half the increase to new contracting and stating AR should decline by Q2 or "certainly by Q3," a timeline the report says was not met through September 2026.


Notable Details

  • BillionToOne's $9.99 "BabyPeek" add-on reportedly promised predictions like eye color, curly hair, and whether a child would dislike cilantro, but the report says it was available only when bundled with the carrier-screening-inclusive Unity Complete test.
  • LinkedIn data cited in the report identify 33 current and former BillionToOne sales representatives, about 14% of the sales force, who previously worked at Progenity, which paid a $49 million settlement in 2020 over alleged fraudulent billing and kickbacks; the report also notes BillionToOne's VP of Reimbursement and eight other employees previously worked at Sequenom, accused of a patient price-capping scheme.
  • A former sales representative said BillionToOne reduced patient bills to $99 or $0 for "really key" physicians' patients, and that managers "pretty much always approve that stuff."
  • The report says BillionToOne's October 2026 study comparing its oncology test with Natera's Signatera excluded 21 paired cases showing discordant results, and that including them would cut the study's reported 94% concordance rate to 73%.
  • Six top insiders sold an estimated $58.5 million in stock after the May 2026 lockup expiration and have registered 10b5-1 plans to sell roughly $24.5 million more.

"You won't find what you don't look for."

Fuzzy Panda Research uses this line to summarize its allegation that BillionToOne's low-risk follow-up methodology, often limited to text-message surveys, was poorly designed to detect false negatives.


FAQs

What is BLLN stock and why is it under scrutiny?

BLLN is the ticker for BillionToOne, Inc., a genetic-testing company whose prenatal and oncology products are the subject of a short report by Fuzzy Panda Research. The report alleges the company's billing practices, regulatory disclosures, and product marketing may not hold up to scrutiny, which could pressure the stock if the claims prove out.

What does BillionToOne, Inc. do?

BillionToOne makes prenatal genetic tests, including Unity and the bundled Unity Complete, as well as oncology tests sold under the Northstar Response and Northstar Select names. The report says Unity tests represented 86% of company revenue and that the company has claimed to test roughly 1 in 10 U.S. babies.

What did Fuzzy Panda Research allege about BillionToOne?

Fuzzy Panda Research, which discloses a short position in the stock, alleges that BillionToOne failed to disclose a Tennessee Medicaid fraud investigation, billed carrier screening at implausibly high rates, waived patient costs without income verification, and overstated the performance of both its prenatal and oncology tests. The firm estimates these issues could remove a majority of the company's EBITDA in its base case.

What did Tennessee investigators find about BillionToOne's billing?

Per Fuzzy Panda Research's review of Tennessee public records, the state's Office of Program Integrity found "a credible allegation of fraud," cited a "Pattern of Inappropriate Billing," and referred BillionToOne to the Tennessee Bureau of Investigation's Medicaid Fraud Division. The report says the investigation reportedly began in 2024 after the state received 11 fraud tips, and that the case remained in "MFCD Review" status with new files added into early 2026.

What is the carrier-screening allegation about BillionToOne's Unity test?

The report cites Michigan Medicaid data showing BillionToOne billed carrier screening alongside 88% of its NIPT tests, compared with 32% for Natera and 31% for Myriad. Because carrier screening is generally performed only once per person, the report argues this rate implies widespread unnecessary or duplicate testing, a claim a prenatal genetic counselor supported by saying genetics "don't change."

What is BillionToOne's financial-assistance program, and why is it controversial?

According to the report, BillionToOne capped or eliminated patient out-of-pocket costs, with figures cited ranging from $0 to $349 depending on the source, without verifying household income through W-2s or similar documentation. A former senior executive is quoted calling the practice "against the law" and a possible Stark-law violation, while the report frames it as a potential illegal inducement.

Are BillionToOne's oncology tests facing credibility issues?

Multiple oncologists quoted in the report described Northstar Response as undifferentiated from competitors like Natera's Signatera, Guardant, and Tempus, with some ranking it their third choice or discontinuing use. The report also alleges BillionToOne's October 2026 comparison study excluded discordant results that would have lowered its reported concordance rate.

Have BillionToOne insiders been selling stock?

Per the Q3 Form 10-Q cited in the report, the company's top six insiders sold an estimated $58.5 million in stock since the May 2026 lockup expiration and subsequently registered new Rule 10b5-1 plans to sell approximately $24.5 million more, with that selling window expected to open about one month after the report's publication.


Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://fuzzypandaresearch.com/billiontoone-undisclosed-fraudulent-deductible-capping-medicaid-inappropriate-billing/?utm_source=rss&utm_medium=rss&utm_campaign=billiontoone-undisclosed-fraudulent-deductible-capping-medicaid-inappropriate-billing, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.